Document is current
Any future updates will be listed below
-
Authors
Acera-Mateos, Mario
Adiconis, Xian
Li, Jessica-Kanglin
Marchese, Domenica
Caratù, Ginevra
Hon, Chung-Chau
Tiwari, Prabha
Kojima, Miki
Vieth, Beate
Murphy, Michael A.
Simmons, Sean K.
Lefevre, Thomas
Claes, Irene
O’Connor, Christopher L.
Menon, Rajasree
Otto, Edgar A.
Ando, Yoshinari
Vandereyken, Katy
Kretzler, Matthias
Bitzer, Markus
Fraenkel, Ernest
Voet, Thierry
Enard, Wolfgang
Carninci, Piero
Heyn, Holger
Levin, Joshua Z.
Mereu, Elisabetta
-
Funding
Funding for this research was provided by:
Chan Zuckerberg Initiative (CZI) Seed Networks (CZF2019-002436)
Ramón y Cajal fellowship (RYC2021-032359-I)
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 5 February 2026
First Online: 13 March 2026
Declarations
:
: Human kidney tissue samples used in this study were obtained from participants enrolled in the PRECISE cohort at the University of Michigan. The PRECISE study was approved by the Institutional Review Board (IRB) of the University of Michigan under approval numbers HUM00165536 and HUM00052918. All participants provided written informed consent for participation in the study and for the use of their samples and associated data for research and publication purposes. All experimental procedures were conducted in accordance with the ethical standards of the institutional research committees and in compliance with the Declaration of Helsinki and its later amendments.
: All participants enrolled in this study provided written informed consent for the collection, analysis, and publication of de-identified biological samples and associated data. No individual-level identifying information is included in this manuscript.
: H.H. is co-founder and Chief Scientific Officer of Omniscope, a Scientific Advisory Board member at Nanostring and Mirxes, a consultant for Moderna and Singularity, and has received honoraria from Genentech. T.V. is co-inventor on licensed patents WO/2011/157846 (Methods for haplotyping single cells), WO/2014/053664 (High-throughput genotyping by sequencing low amounts of genetic material) and WO/2015/028576 (Haplotyping and copy number typing using polymorphic variant allelic frequencies). M.Kretzler reports grants and contracts through the University of Michigan with Chan Zuckerberg Initiative, AstraZeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Janssen, Boehringer-Ingelheim, Moderna, European Union Innovative Medicine Initiative, Certa Therapeutics, Chinook, amfAR, Angion, RenalytixAI, Travere, Regeneron, IONIS. Consulting fees through the University of Michigan from Astellas, Poxel, Janssen and UCB. In addition, M.Kretzler has a patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed.
